BTIG raises target for Avita Medical stock from USD 11.00 to USD 15.00
Published on 10/19/2026 at 00:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSTarget revision and revenue growth
- BTIG lifted its Avita Medical target on October 12, 2026.
- Second-quarter revenue reached USD 21.70 million, up 18.00 percent year over year.
- Full-year 2026 revenue guidance stands at USD 86 million to USD 89 million.
Avita Medical (AU000000AVH4) received a higher valuation marker when BTIG raised its price target from USD 11.00 to USD 15.00 on October 12, 2026, while keeping a Buy rating, as Markets Insider reported. The change adds an analyst reference point after a stronger second quarter and raised revenue guidance.
Revenue growth strengthens the case
AVITA Medical reported USD 21.70 million in second-quarter 2026 revenue, an 18.00 percent year-over-year increase and a 13.00 percent sequential gain, according to Benzinga. Gross margin reached 81.90 percent in the quarter, compared with 81.20 percent in the year-earlier quarter, while operating expenses were USD 24.60 million.
What does growth mean for cash?
Management raised full-year 2026 revenue guidance to USD 86 million to USD 89 million from USD 80 million to USD 85 million, representing 20.00 percent to 24.00 percent growth over USD 71.60 million in 2025, as reported by Simply Wall St. The company also guided to cash flow breakeven during the fourth quarter of 2026. Net cash use improved to USD 3.20 million in the second quarter, while cash, cash equivalents and marketable securities totaled USD 11.10 million.
Three events reshape the case
On August 6, 2026, Avita Medical reported second-quarter revenue of USD 21.70 million and adjusted earnings per share of minus USD 0.25, according to MarketBeat. On September 16, 2026, the company raised its 2026 revenue guidance to USD 86 million to USD 89 million, according to Simply Wall St. On October 12, 2026, BTIG raised its target from USD 11.00 to USD 15.00, as Markets Insider reported.
Dates investors can track
MarketBeat lists November 5, 2026 as the date for Avita Medical's third-quarter 2026 earnings report, while the new Category 1 CPT code family for skin cell suspension autograft is scheduled to replace the existing structure on January 1, 2027, according to MarketBeat and Benzinga. The reimbursement transition could affect adoption and sales execution, making the next report important for testing the guidance.
Frankfurt quote stays dated
The last available euro price was EUR 11.70 on Frankfurt Stock Exchange on October 16, 2026. Avita Medical's primary listing is Nasdaq under ticker RCEL, and its market capitalization was USD 324.0 million on October 16, 2026, with a 52-week range of USD 3.22 to USD 13.73.
The further course of trading is shown by the continuously updated real-time quote of Avita Medical stock.
Avita Medical market facts
- Company: Avita Medical, Inc.
- ISIN: AU000000AVH4
- Ticker: RCEL
- Primary exchange: Nasdaq
- Market capitalization: USD 324.0 million (as of October 16, 2026)
- 52-week range: USD 3.22-13.73 (as of October 16, 2026)
- Sector / Industry: Healthcare / Medical Devices
- Index membership: Nasdaq Composite
Market context: Market report Nasdaq Composite.
